Do analysts rate SLN or JATT?

Silence Therapeutics presently has a consensus target price of $55.00, suggesting a potential upside of 782.83%. Given Silence Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Silence Therapeutics is more favorable than JATT Acquisition. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Silence Therapeutics 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.80 JATT Acquisition 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has preferable valuation & earnings, SLN or JATT?

JATT Acquisition has lower revenue, but higher earnings than Silence Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Silence Therapeutics $560K 525.55 -$88.61M -$1.59 N/A JATT Acquisition N/A N/A $6.85M N/A N/A

Do analysts rate JATT or RZLT?

Rezolute has a consensus target price of $8.75, suggesting a potential upside of 114.46%. Given Rezolute's stronger consensus rating and higher probable upside, analysts clearly believe Rezolute is more favorable than JATT Acquisition. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score JATT Acquisition 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Rezolute 1 Sell rating(s) 2 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.64

Which has preferable earnings & valuation, JATT or RZLT?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio JATT Acquisition N/A N/A $6.85M N/A N/A Rezolute N/A N/A -$74.41M -$0.82 N/A

Is JATT or RZLT more profitable?

JATT Acquisition's return on equity of -49.58% beat Rezolute's return on equity. Company Net Margins Return on Equity Return on Assets JATT Acquisition N/A -49.58% 2.84% Rezolute N/A -58.82% -54.48%

Do analysts rate PRLD or JATT?

Prelude Therapeutics currently has a consensus price target of $7.67, indicating a potential upside of 99.65%. Given Prelude Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Prelude Therapeutics is more favorable than JATT Acquisition. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Prelude Therapeutics 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.40 JATT Acquisition 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has higher earnings and valuation, PRLD or JATT?

JATT Acquisition has lower revenue, but higher earnings than Prelude Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Prelude Therapeutics $12.14M 25.19 -$99.50M -$1.00 N/A JATT Acquisition N/A N/A $6.85M N/A N/A

Is PRLD or JATT more profitable?

JATT Acquisition's return on equity of -49.58% beat Prelude Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Prelude Therapeutics N/A -118.24% -66.12% JATT Acquisition N/A -49.58% 2.84%

Do analysts recommend JATT or TENX?

Tenax Therapeutics has a consensus target price of $29.67, suggesting a potential upside of 181.47%. Given Tenax Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Tenax Therapeutics is more favorable than JATT Acquisition. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score JATT Acquisition 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Tenax Therapeutics 1 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.83

Which has better earnings and valuation, JATT or TENX?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio JATT Acquisition N/A N/A $6.85M N/A N/A Tenax Therapeutics N/A N/A -$52.60M -$1.40 N/A

Is JATT or TENX more profitable?

JATT Acquisition's return on equity of -49.58% beat Tenax Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets JATT Acquisition N/A -49.58% 2.84% Tenax Therapeutics N/A -56.32% -53.12%

Do analysts recommend FATE or JATT?

Fate Therapeutics presently has a consensus target price of $5.13, suggesting a potential upside of 168.32%. Given Fate Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Fate Therapeutics is more favorable than JATT Acquisition. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Fate Therapeutics 1 Sell rating(s) 3 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.29 JATT Acquisition 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has better valuation & earnings, FATE or JATT?

JATT Acquisition has lower revenue, but higher earnings than Fate Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Fate Therapeutics $6.65M 33.48 -$136.32M -$1.09 N/A JATT Acquisition N/A N/A $6.85M N/A N/A

JATT Acquisition (JATT) Competitors

$10.37 -0.06 (-0.54%)

As of 06/8/2026 01:12 PM Eastern

Compare

JATT vs. SLN, RZLT, PRLD, TENX, and FATE

Should you buy JATT Acquisition stock or one of its competitors? MarketBeat compares JATT Acquisition with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with JATT Acquisition include Silence Therapeutics (SLN), Rezolute (RZLT), Prelude Therapeutics (PRLD), Tenax Therapeutics (TENX), and Fate Therapeutics (FATE). These companies are all part of the "pharmaceutical products" industry.

How does JATT Acquisition compare to Silence Therapeutics?

Silence Therapeutics (NASDAQ:SLN) and JATT Acquisition (NYSE:JATT) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, profitability, analyst recommendations, dividends, valuation, earnings, media sentiment and risk.

JATT Acquisition has lower revenue, but higher earnings than Silence Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Silence Therapeutics	$560K	525.55	-$88.61M	-$1.59	N/A
JATT Acquisition	N/A	N/A	$6.85M	N/A	N/A

98.7% of Silence Therapeutics shares are owned by institutional investors. Comparatively, 48.0% of JATT Acquisition shares are owned by institutional investors. 3.0% of Silence Therapeutics shares are owned by company insiders. Comparatively, 20.0% of JATT Acquisition shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

JATT Acquisition has a net margin of 0.00% compared to Silence Therapeutics' net margin of -8,943.86%. JATT Acquisition's return on equity of -49.58% beat Silence Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Silence Therapeutics	-8,943.86%	-105.34%	-52.79%
JATT Acquisition	N/A	-49.58%	2.84%

Silence Therapeutics presently has a consensus target price of $55.00, suggesting a potential upside of 782.83%. Given Silence Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Silence Therapeutics is more favorable than JATT Acquisition.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Silence Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80
JATT Acquisition	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, Silence Therapeutics' average media sentiment score of 0.00 equaled JATT Acquisition'saverage media sentiment score.

Company	Overall Sentiment
Silence Therapeutics	Neutral
JATT Acquisition	Neutral

Summary

Silence Therapeutics beats JATT Acquisition on 6 of the 11 factors compared between the two stocks.

How does JATT Acquisition compare to Rezolute?

JATT Acquisition (NYSE:JATT) and Rezolute (NASDAQ:RZLT) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, profitability, media sentiment, earnings, analyst recommendations and dividends.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
JATT Acquisition	N/A	N/A	$6.85M	N/A	N/A
Rezolute	N/A	N/A	-$74.41M	-$0.82	N/A

JATT Acquisition's return on equity of -49.58% beat Rezolute's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
JATT Acquisition	N/A	-49.58%	2.84%
Rezolute	N/A	-58.82%	-54.48%

In the previous week, Rezolute had 14 more articles in the media than JATT Acquisition. MarketBeat recorded 14 mentions for Rezolute and 0 mentions for JATT Acquisition. Rezolute's average media sentiment score of 0.47 beat JATT Acquisition's score of 0.00 indicating that Rezolute is being referred to more favorably in the news media.

Company	Overall Sentiment
JATT Acquisition	Neutral
Rezolute	Neutral

Rezolute has a consensus target price of $8.75, suggesting a potential upside of 114.46%. Given Rezolute's stronger consensus rating and higher probable upside, analysts clearly believe Rezolute is more favorable than JATT Acquisition.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
JATT Acquisition	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Rezolute	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64

48.0% of JATT Acquisition shares are owned by institutional investors. Comparatively, 83.0% of Rezolute shares are owned by institutional investors. 20.0% of JATT Acquisition shares are owned by insiders. Comparatively, 14.8% of Rezolute shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Rezolute beats JATT Acquisition on 6 of the 10 factors compared between the two stocks.

How does JATT Acquisition compare to Prelude Therapeutics?

Prelude Therapeutics (NASDAQ:PRLD) and JATT Acquisition (NYSE:JATT) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, media sentiment, risk, institutional ownership, profitability and analyst recommendations.

79.7% of Prelude Therapeutics shares are owned by institutional investors. Comparatively, 48.0% of JATT Acquisition shares are owned by institutional investors. 49.2% of Prelude Therapeutics shares are owned by insiders. Comparatively, 20.0% of JATT Acquisition shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

JATT Acquisition's return on equity of -49.58% beat Prelude Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Prelude Therapeutics	N/A	-118.24%	-66.12%
JATT Acquisition	N/A	-49.58%	2.84%

In the previous week, Prelude Therapeutics' average media sentiment score of 0.00 equaled JATT Acquisition'saverage media sentiment score.

Company	Overall Sentiment
Prelude Therapeutics	Neutral
JATT Acquisition	Neutral

JATT Acquisition has lower revenue, but higher earnings than Prelude Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Prelude Therapeutics	$12.14M	25.19	-$99.50M	-$1.00	N/A
JATT Acquisition	N/A	N/A	$6.85M	N/A	N/A

Prelude Therapeutics currently has a consensus price target of $7.67, indicating a potential upside of 99.65%. Given Prelude Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Prelude Therapeutics is more favorable than JATT Acquisition.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Prelude Therapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
JATT Acquisition	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

Prelude Therapeutics beats JATT Acquisition on 6 of the 9 factors compared between the two stocks.

How does JATT Acquisition compare to Tenax Therapeutics?

JATT Acquisition (NYSE:JATT) and Tenax Therapeutics (NASDAQ:TENX) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, risk, media sentiment, dividends, earnings and valuation.

Tenax Therapeutics has a consensus target price of $29.67, suggesting a potential upside of 181.47%. Given Tenax Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Tenax Therapeutics is more favorable than JATT Acquisition.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
JATT Acquisition	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Tenax Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83

JATT Acquisition's return on equity of -49.58% beat Tenax Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
JATT Acquisition	N/A	-49.58%	2.84%
Tenax Therapeutics	N/A	-56.32%	-53.12%

In the previous week, Tenax Therapeutics had 1 more articles in the media than JATT Acquisition. MarketBeat recorded 1 mentions for Tenax Therapeutics and 0 mentions for JATT Acquisition. JATT Acquisition's average media sentiment score of 0.00 equaled Tenax Therapeutics'average media sentiment score.

Company	Overall Sentiment
JATT Acquisition	Neutral
Tenax Therapeutics	Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
JATT Acquisition	N/A	N/A	$6.85M	N/A	N/A
Tenax Therapeutics	N/A	N/A	-$52.60M	-$1.40	N/A

48.0% of JATT Acquisition shares are held by institutional investors. Comparatively, 1.7% of Tenax Therapeutics shares are held by institutional investors. 20.0% of JATT Acquisition shares are held by company insiders. Comparatively, 3.7% of Tenax Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

JATT Acquisition and Tenax Therapeutics tied by winning 5 of the 10 factors compared between the two stocks.

How does JATT Acquisition compare to Fate Therapeutics?

Fate Therapeutics (NASDAQ:FATE) and JATT Acquisition (NYSE:JATT) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, profitability, analyst recommendations, dividends, earnings, risk, valuation and institutional ownership.

Fate Therapeutics presently has a consensus target price of $5.13, suggesting a potential upside of 168.32%. Given Fate Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Fate Therapeutics is more favorable than JATT Acquisition.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fate Therapeutics	1 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.29
JATT Acquisition	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, Fate Therapeutics had 4 more articles in the media than JATT Acquisition. MarketBeat recorded 4 mentions for Fate Therapeutics and 0 mentions for JATT Acquisition. Fate Therapeutics' average media sentiment score of 0.00 equaled JATT Acquisition'saverage media sentiment score.

Company	Overall Sentiment
Fate Therapeutics	Neutral
JATT Acquisition	Neutral

JATT Acquisition has a net margin of 0.00% compared to Fate Therapeutics' net margin of -2,056.79%. JATT Acquisition's return on equity of -49.58% beat Fate Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Fate Therapeutics	-2,056.79%	-58.89%	-39.39%
JATT Acquisition	N/A	-49.58%	2.84%

97.5% of Fate Therapeutics shares are held by institutional investors. Comparatively, 48.0% of JATT Acquisition shares are held by institutional investors. 4.7% of Fate Therapeutics shares are held by insiders. Comparatively, 20.0% of JATT Acquisition shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

JATT Acquisition has lower revenue, but higher earnings than Fate Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fate Therapeutics	$6.65M	33.48	-$136.32M	-$1.09	N/A
JATT Acquisition	N/A	N/A	$6.85M	N/A	N/A

Summary

Fate Therapeutics beats JATT Acquisition on 6 of the 11 factors compared between the two stocks.

Get JATT Acquisition News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding JATT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

JATT vs. The Competition

Export

Metric	JATT Acquisition	Biological Products Industry	Medical Sector	NYSE Exchange
Market Cap	$83.25M	$349.17M	$6.48B	$23.05B
Dividend Yield	N/A	N/A	2.67%	4.10%
P/E Ratio	N/A	N/A	23.69	30.30
Price / Sales	N/A	143.64	512.55	22.46
Price / Cash	27.08	22.44	26.99	18.46
Price / Book	-19.57	4.71	10.46	4.61
Net Income	$6.85M	-$141.03M	$3.57B	$1.07B
7 Day Performance	-1.99%	-4.94%	0.25%	-2.04%
1 Month Performance	-3.54%	-4.54%	3.24%	-1.23%
1 Year Performance	723.33%	50.22%	22.21%	20.54%

JATT Acquisition Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
JATT JATT Acquisition	N/A	$10.37 -0.5%	N/A	+723.3%	$83.25M	N/A	N/A	3
SLN Silence Therapeutics	2.3924 of 5 stars	$6.90 +0.6%	$55.00 +697.1%	+14.5%	$324.03M	$560K	N/A	100
RZLT Rezolute	2.923 of 5 stars	$3.30 +0.9%	$8.75 +165.2%	-7.9%	$314.88M	N/A	N/A	40	Analyst Upgrade
PRLD Prelude Therapeutics	3.1665 of 5 stars	$3.92 -0.3%	$7.67 +95.6%	+272.8%	$313.01M	$12.14M	N/A	120
TENX Tenax Therapeutics	2.582 of 5 stars	$11.87 +1.5%	$29.67 +149.9%	+73.9%	$310.08M	N/A	N/A	9

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:JATT) was last updated on 6/9/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

JATT Acquisition (JATT) Competitors

JATT vs. SLN, RZLT, PRLD, TENX, and FATE

How does JATT Acquisition compare to Silence Therapeutics?

Summary

How does JATT Acquisition compare to Rezolute?

Summary

How does JATT Acquisition compare to Prelude Therapeutics?

Summary

How does JATT Acquisition compare to Tenax Therapeutics?

Summary

How does JATT Acquisition compare to Fate Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

JATT vs. The Competition

JATT Acquisition Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

JATT Acquisition (JATT) Competitors

JATT vs. SLN, RZLT, PRLD, TENX, and FATE

How does JATT Acquisition compare to Silence Therapeutics?

Which has preferable valuation & earnings, SLN or JATT?

Do institutionals & insiders have more ownership in SLN or JATT?

Is SLN or JATT more profitable?

Do analysts rate SLN or JATT?

Does the media prefer SLN or JATT?

Summary

How does JATT Acquisition compare to Rezolute?

Which has preferable earnings & valuation, JATT or RZLT?

Is JATT or RZLT more profitable?

Does the media prefer JATT or RZLT?

Do analysts rate JATT or RZLT?

Do insiders and institutionals hold more shares of JATT or RZLT?

Summary

How does JATT Acquisition compare to Prelude Therapeutics?

Do institutionals & insiders hold more shares of PRLD or JATT?

Is PRLD or JATT more profitable?

Does the media favor PRLD or JATT?

Which has higher earnings and valuation, PRLD or JATT?

Do analysts rate PRLD or JATT?

Summary

How does JATT Acquisition compare to Tenax Therapeutics?

Do analysts recommend JATT or TENX?

Is JATT or TENX more profitable?

Does the media favor JATT or TENX?

Which has better earnings and valuation, JATT or TENX?

Do institutionals & insiders have more ownership in JATT or TENX?

Summary

How does JATT Acquisition compare to Fate Therapeutics?

Do analysts recommend FATE or JATT?

Does the media favor FATE or JATT?

Is FATE or JATT more profitable?

Do insiders and institutionals hold more shares of FATE or JATT?

Which has better valuation & earnings, FATE or JATT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

JATT vs. The Competition

JATT Acquisition Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools